Table 1.
Characteristics of patients for the transcriptomic studies.
| SR (RNA-Seq)* | SR (miR microarray) | pAF | |
|---|---|---|---|
| Patients, n | 4 | 4 | 4 |
| Gender, m/f | 2/2 | 3/1 | 3/1 |
| Age, y | 65.0±4.1 | 70.5±1.9 | 71.3±2.9 |
| Body mass index, kg/m2 | 27.4±1.5 | 26.9±1.5 | 25.2±1.9 |
| CAD, n | 3 | 3 | 3 |
| MVD/AVD, n | 0 | 0 | 0 |
| CAD+MVD/AVD, n | 1 | 1 | 1 |
| Hypertension, n | 4 | 4 | 4 |
| Diabetes, n | 2 | 1 | 1 |
| Hyperlipidemia, n | 4 | 4 | 3 |
| LVEF, % | 49.7±12.9 | 51.5±9.8 | 51.3±8.1 |
| Digitalis, n | 1 | 1 | 1 |
| ACE inhibitors, n | 3 | 2 | 4 |
| AT1 blockers, n | 0 | 0 | 0 |
| β-Blockers, n | 4 | 3 | 3 |
| Dihydropyridines, n | 1 | 1 | 3 |
| Diuretics, n | 2 | 2 | 1 |
| Nitrates, n | 0 | 0 | 1 |
| Lipid-lowering drugs, n | 4 | 3 | 3 |
*
With the exception of one SR sample, all the other SR and pAF samples were used for both the RNA-Seq and miR microarray experiments. Values are presented as mean±SEM or number of patients. SR, patients in sinus rhythm; pAF, paroxysmal atrial fibrillation patients; CAD, coronary artery disease, MVD/AVD, mitral/aortic valve disease; LVEF, left ventricular ejection fraction; ACE, angiotensin-converting enzyme; AT, angiotensin receptor. No statistical differences were found between SR (RNA-Seq) vs. pAF or SR (miR microarray) vs. pAF using two-tailed Student’s t-test for continuous variables and Fisher’s exact test for categorical variables (all P>0.1).